Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What are Viruses?00:50

What are Viruses?

127.9K
Overview
127.9K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

261
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
261
Hepatic Portal System01:21

Hepatic Portal System

5.6K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.6K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

281
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
281
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

219
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
219
Tonicity in Animals00:59

Tonicity in Animals

123.4K
The tonicity of a solution determines if a cell gains or loses water in that solution. The tonicity depends on the permeability of the cell membrane for different solutes and the concentration of nonpenetrating solutes in the solution within and outside of the cell. If a semipermeable membrane hinders the passage of some solutes but allows water to follow its concentration gradient, water moves from the side with low osmolarity (i.e., less solute) to the side with higher osmolarity (i.e.,...
123.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A non-inferiority trial comparing manual and automated high-level disinfection for reprocessing of transabdominal and transvaginal ultrasound probes.

Antimicrobial resistance and infection control·2026
Same author

Assessing ultraviolet-C light-emitting diode disinfection of disposable video laryngoscope blades: a sustainable approach through an integrated microbiological, environmental, economic, and regulatory evaluation.

BJA open·2026
Same author

[Knocking on the cell's door: HEVidence of how HEV gets in].

Medecine sciences : M/S·2026
Same author

[The hepatitis E virus ORF2 capsid protein, a cornerstone of viral persistence].

Medecine sciences : M/S·2026
Same author

Fluorescent virus lights up on a new drug for chronic hepatitis E.

Gut·2026
Same author

Update on the molecular and cellular biology of hepatitis E virus and therapeutic opportunities.

Antiviral research·2026
Same journal

Correction: Bulatov et al. Camelpox Virus in Western Kazakhstan: Assessment of the Role of Local Fauna as Reservoirs of Infection. <i>Viruses</i> 2024, <i>16</i>, 1626.

Viruses·2026
Same journal

Correction: Franco et al. Whole Blood Volume-Based Absolute Quantification of HTLV-1 Proviral Load: A Comparative Method Evaluation Study. <i>Viruses</i> 2026, <i>18</i>, 580.

Viruses·2026
Same journal

Correction: Medkour et al. Adenovirus Infections in African Humans and Wild Non-Human Primates: Great Diversity and Cross-Species Transmission. <i>Viruses</i> 2020, <i>12</i>, 657.

Viruses·2026
Same journal

Burden of Malaria and Dengue Across Global, Asian, and Chinese Populations Based on GBD 2021 Data: A Quantitative Assessment of Importation Risks to China.

Viruses·2026
Same journal

First Report of <i>Orthonairovirus songlingense</i> in <i>Haemaphysalis concinna</i> Ticks from Russia.

Viruses·2026
Same journal

Epidemiological and Virological Characteristics of H9N2 Avian Influenza Virus in Jiangsu Province, China, 2024.

Viruses·2026
See all related articles

Related Experiment Video

Updated: Jan 23, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Animal Models for Hepatitis E virus.

Laura Corneillie1, Dominic H Banda2, Philip Meuleman3

  • 1Laboratory of Liver Infectious Diseases, Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium. laura.corneillie@ugent.be.

Viruses
|June 21, 2019
PubMed
Summary
This summary is machine-generated.

Hepatitis E virus (HEV) causes millions of infections annually and is a growing concern globally. This review details animal models crucial for understanding HEV pathogenesis and developing treatments.

Keywords:
Hepatitis E virusanimal modelcross-species infectionpathogenicityvaccinezoonosis

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.3K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

Related Experiment Videos

Last Updated: Jan 23, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.3K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

Area of Science:

  • Virology
  • Infectious Diseases
  • Public Health

Background:

  • Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis, affecting millions worldwide.
  • Once thought to be restricted to developing nations, HEV is increasingly recognized as a significant health issue in Western countries.
  • HEV belongs to the Orthohepevirus A species within the Hepeviridae family, with related viruses found in various animal reservoirs.

Purpose of the Study:

  • To provide a comprehensive overview of existing animal models for Hepatitis E virus.
  • To analyze the characteristics of these animal models.
  • To highlight their utility in studying HEV's viral life cycle, cross-species transmission, pathogenesis, and therapeutic strategies.

Main Methods:

  • Review of existing literature on HEV animal models.
  • Analysis of characteristics and applications of various models.
  • Synthesis of information on HEV research advancements.

Main Results:

  • Several animal models have been developed to study HEV, addressing limitations of cell culture systems.
  • These models aid in understanding HEV's basic biology, including its life cycle and zoonotic potential.
  • Animal models are instrumental in evaluating potential preventative and therapeutic interventions for HEV infections.

Conclusions:

  • Animal models are essential tools for advancing HEV research, from basic science to clinical applications.
  • Further development and utilization of these models will be critical for controlling HEV globally.
  • Understanding cross-species transmission through animal models is key to preventing future outbreaks.